Search Results

Deals

Ophthotech Reports Fourth Quarter and Full Year 2018 Financial and Operating Results

Ophthotech Corporation announced financial and operating results for the fourth quarter and full year ended December 31, 2018 and provided a business update.

February 26, 2019

·

12 min read

Deals

Ophthotech Expands Innovative Retinal Disease Pipeline with Acquisition of Versant Ventures’ Inception 4

- Ophthotech Gains HtrA1 Inhibitors to Treat Age-related Retinal Diseases -

October 31, 2018

·

6 min read

Business

Ophthotech Obtains Exclusive Global License to AAV Gene Therapy Program for BEST1 Related Retinal Diseases

Ophthotech Corporation (NASDAQ: OPHT) announced today that the Company has converted its option and entered into an exclusive global license agreement with the University of Pennsylvania

April 11, 2019

·

4 min read

Deals

Ophthotech Corporation to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Tuesday, February 26, 2019

Ophthotech Corporation announced that it will report its fourth quarter and full year 2018 financial and operating results on Tuesday, February 26, 2019.

February 19, 2019

·

1 min read

Pharm Country

Ophthotech Corporation to Present at the 37th Annual J.P. Morgan Healthcare Conference

Ophthotech Corporation (NASDAQ: OPHT) announced today that Glenn P. Sblendorio, Chief Executive Officer and President, will present an overview of the Company at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA

January 3, 2019

·

1 min read

Business

Ophthotech Reports First Quarter 2018 Financial and Operating Results

Ophthotech is a science-driven biopharmaceutical company specializing in the development of novel therapies to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases

May 9, 2018

·

9 min read

Business

Ophthotech Transitions to a Gene Therapy Focused Company Developing Treatments for Orphan Inherited Retinal Diseases and Changes Name to IVERIC bio

Ophthotech Corporation announced that as part of its transition strategy to focus on discovering and developing novel gene therapy solutions to treat orphan inherited retinal diseases (IRDs) with unmet medical needs, the Company is changing its name to IVERIC bio, Inc.

April 16, 2019

·

4 min read

Business

Ophthotech Corporation to Report Second Quarter 2018 Financial Results and Host Conference Call on Wednesday, August 1, 2018

Ophthotech Corporation announced that it will report its second quarter 2018 financial and operating results on Wednesday, August 1, 2018.

July 25, 2018

·

1 min read

Pharm Country

Ophthotech to Present at the Alliance for Regenerative Medicine’s (ARM) 7th Annual Cell & Gene Therapy Investor Day

Ophthotech Corporation (Nasdaq: OPHT) announced today that Kourous A. Rezaei, M.D., Chief Medical Officer, will present an overview of the Company at the Alliance for Regenerative Medicine’s (ARM) 7th Annual Cell and Gene Therapy Investor Day in New York, NY, on Thursday, March 21, 2019 at 2:15 p.m. Eastern Time.

March 14, 2019

·

1 min read

Business

Ophthotech Expands Gene Therapy Pipeline in Orphan Retinal Diseases with Exclusive Option for Novel Product Candidates to Treat Best Vitelliform Macular Dystrophy (Best Disease)

Ophthotech Enters into Second Series of Gene Therapy Agreements with the University of Pennsylvania and the University of Florida for Exclusive Option for Novel Product Candidates to Treat Best Disease

October 31, 2018

·

6 min read